Homepage | Set Home | Add to Favorites
Member

Zhejiang Fengfu Pharma Co.,Limited


Products
  • No Category
Search
 

Friends links
Vonoprazan Fumarate CAS 1260141-27-2
Click image to view full size image
Product: Views:221Vonoprazan Fumarate CAS 1260141-27-2 
Unit price: Negotiable
MOQ:
Quantity:
Delivery date: Since the payment date Days delivery
Valid until: Long-term effective
Last updated: 2024-05-23 08:05
  Inquiry
Details

Vonoprazan fumarate is a salt form of vonoprazan, which is the active pharmaceutical ingredient. It is primarily used for the treatment of acid-related gastrointestinal disorders, such as gastroesophageal reflux disease (GERD), gastric ulcers, and duodenal ulcers.

 

Vonoprazan works by selectively and reversibly inhibiting the H+/K+-ATPase enzyme, commonly known as the proton pump, in the stomach's parietal cells. This inhibition reduces the production of gastric acid, leading to effective suppression of acid secretion.

 

Item

Standard Regulation

Test Result

Appearance

Appearance

White to off-white crystal or crystalline powder

Off-white crystalline powder

Analysis

Fluorine check

3.9%-4.3%

4.2%

Chlorides

Not more than 0.05%

Complies

Ammonium salt

Not more than 0.05%

Complies

Sulfate

Not more than 0.05%

Complies

Water

Not more than 0.40%

Complies

Residue on Ignition

Not more than 0.10%

0.021%

Heavy metals

Not more than 20ppm

Complies

Organic Impurities

Single impurity: not more than 0.15%

0.062%

Total impurity: not more than 1.0%

0.25%

Residual Solvents

Methanol: not more than 0.30%

Not detected

Ethanol: not more than 0.50%

Not detected

Ethyl acetate: not more than 0.50%

Not detected

Dichloromethane: not more than 0.060%

Not detected

Acetonitrile: not more than 0.041%

Not detected

Tetrahydrofuran: not more than 0.072%

Not detected

Benzene: not moare than 0.020%

Not detected

Pyridine: not more than 0.020%

Not detected

N,N-Dimethylacetamide: not more than 0.10%

Not detected

Methylamine: not more than 0.10%

Not detected

Acetic acid: not more than 0.50%

Not detected

Fumaric acid content

23.9%-26.4%

24.5%

Assay

NLT 98.0% and NMT 102.0% of C17H16FN3O2S.C4H4O4, calculated on the anhydrous basis

99.2%

Vonoprazan Fumarate TAK-438 1260141-27-2

Product: Vonoprazan Fumarate TAK-438

Another name: TAK438; TAK-438

CAS No.: 1260141-27-2

Application: It effectively terminates the secretion of gastric acid, thereby achieving acid suppression

Product Category: Gastrointestinal API, Pepsin digestive enzyme API, Pancreatin digestive enzyme API

Molecular Formula: C21H20FN3O6S

MDL Number: MFCD18633280

 

1. Payment term

TT, LC

2. Delivery date

Negotiable

3. Market

Middle East / Africa / Asia / South America / Europe

4. Sample

Available

5. Executive standards
CP, EP, IP

6. Qualification certificate
Registration "A" status of raw material packaging, Notification of Approval of marketing application for chemical API, WC, COPP, CEP, EUGMP, US DMF registration number, India Registration certificate, Brazil registration, Malaysia registration, etc.

7. Packaging size specification

Inner package: single-layer polyethylene bag and aluminum foil bag.

Outer package: fiber drum.

Packaging size: 20 kg/drum; 1kg/drum; 5kg/drum.

 

Our Advantage

 

We have branch offices in Dubai and India

we have own reliable & Long-term cooperative & experienced factory

Variety products for selection from China and India

We can customize according to your requirements

We can do OEM & ODM

We can offer N-1 to API

 

Vonoprazan Fumarate 1260141-27-2 FAQ

 

Q: How is Vonoprazan Fumarate API administered?

A: Vonoprazan Fumarate API is typically administered orally in the form of tablets or capsules. The recommended dosage and duration of treatment may vary depending on the specific condition being treated and individual patient factors. It is important to follow the prescribing information and guidance provided by healthcare professionals.

Q: Are there any known side effects of Vonoprazan Fumarate API?

A: Like any medication, Vonoprazan Fumarate API may have potential side effects. Some common side effects reported include headache, diarrhea, constipation, abdominal pain, and nausea. However, not all individuals may experience these side effects, and the overall safety profile of Vonoprazan Fumarate API is considered favorable.

Q: Can Vonoprazan Fumarate API be used in certain patient populations?

A: Vonoprazan Fumarate API is generally well-tolerated and can be used in various patient populations, including adults and elderly individuals. However, specific precautions and dosage adjustments may be necessary in patients with certain medical conditions or those taking concomitant medications. It is important to consult with healthcare professionals for individualized guidance.

Q: Can Vonoprazan Fumarate API be used during pregnancy or while breastfeeding?

A: The use of Vonoprazan Fumarate API (TAK-438) during pregnancy or breastfeeding is not well-established, and it is important to consult with a healthcare professional for personalized advice.

Pregnancy: There is limited information available on the safety of Vonoprazan Fumarate API during pregnancy. Animal studies have shown potential risks to the fetus, but there are no adequate and well-controlled studies in pregnant women. The use of this medication during pregnancy should be carefully evaluated, weighing the potential benefits against the potential risks to the fetus.

Breastfeeding: It is not known whether Vonoprazan Fumarate API is excreted in human breast milk. Studies in animals have shown excretion of the drug and its metabolites in milk. Due to the potential risks to the infant, a decision should be made whether to discontinue breastfeeding or to discontinue the medication, taking into account the importance of the medication to the mother.
 
It is crucial to have a discussion with a healthcare professional who can consider the individual circumstances and provide appropriate guidance based on the current knowledge and available information. They can assess the potential risks and benefits and help make an informed decision regarding the use of Vonoprazan Fumarate API during pregnancy or breastfeeding.

 

http://www.richerpharm.com/

Inquiry